PBNP-PTT expanded antigen-specific T cells

PBNP-PTT expanded antigen-specific T cells are an autologous adoptive cell therapy (ACT) product generated using a specialized ex vivo expansion method. The process utilizes Prussian Blue nanoparticle-photothermal therapy (PBNP-PTT) to induce immunogenic cell death in ovarian cancer cells, creating a tumor cell lysate rich in neoepitopes and tumor-associated antigens. This lysate is used to pulse bone marrow-derived dendritic cells, which then selectively stimulate and expand tumor-reactive CD8+ T cells from the patient's own splenic or peripheral blood repertoire. These engineered T cells demonstrate enhanced secretion of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) and exhibit potent cytotoxic activity against ovarian cancer cells. Preclinical studies in immunocompetent murine models have shown that these cells can persist in the tumor microenvironment, reduce tumor burden, and significantly prolong survival, particularly when combined with epigenetic modulators.

Other names

PBNP-PTT-expanded T cellsAntigen-specific T cells engineered with nanoparticle photothermal therapynanoparticle photothermal therapy-engineered T cells